Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Cantor Fitzgerald Downgrades Fulcrum Therapeutics (FULC) to Neutral
September 12, 2024 8:50 AM EDTCantor Fitzgerald analyst Kristen Kluska downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Fulcrum Therapeutics click here. For more ratings news on Fulcrum Therapeutics click here.
Shares of Fulcrum Therapeutics closed at $8.85 yesterday.
... MoreFulcrum Therapeutics (FULC) Reports Topline Results from Phase 3 REACH Trial of Losmapimod
September 12, 2024 6:55 AM EDTFulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance. The safety and tolerability profile of losmapimod was consistent with previously reported studies. The Company will complete a full evaluation of the data it received this week and plans to share the results at an upcoming medical meeting.
We are deeply disappointed that the REACH trial did not... More
